Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The 5-milligram (mg) dose of prasugrel in low body weight (LBW) patients with coronary artery
disease produces a pharmacodynamic response within the same therapeutic range as 10-mg dose
in higher body weight (HBW) patients.